Comparative Pharmacology
Head-to-head clinical analysis: QUINATIME versus QUINIDINE GLUCONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINATIME versus QUINIDINE GLUCONATE.
QUINATIME vs QUINIDINE GLUCONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinine acts by interfering with the parasite's ability to break down hemoglobin, leading to accumulation of toxic heme and parasite death. It also inhibits nucleic acid and protein synthesis in the parasite.
Class Ia antiarrhythmic agent; blocks sodium channels (Nav1.5) and potassium channels (IKr, IKs), prolongs action potential duration and effective refractory period; also has anticholinergic and alpha-adrenergic blocking effects.
600 mg (base) orally every 8 hours for 7 days; or 10 mg/kg (base) intravenously loading dose over 1 hour, then 0.02 mg/kg/min continuous infusion for 3 days, then switch to oral.
324-648 mg orally every 8-12 hours; maximum 3.24 g/day. Also administered IV as quinidine gluconate 200-400 mg (diluted) at a rate ≤1 mL/min.
None Documented
None Documented
Terminal elimination half-life 10-12 hours in healthy adults; prolonged in hepatic impairment.
Terminal elimination half-life: 6-8 hours (range 4-12 hours) in healthy adults; prolonged in HF, renal impairment, or elderly.
Renal: ~20% unchanged; hepatic metabolism (CYP3A4) major route; biliary/fecal: ~80% as metabolites.
Renal: 50-70% unchanged; Biliary/fecal: 20-30%; Hepatic metabolism accounts for 10-30%.
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)